Literature DB >> 4163358

Studies of the Vi (gamma-2c) subgroup of gamma-globulin. A relationship between concentration and genetic type among normal individuals.

W J Yount, H G Kunkel, S D Litwin.   

Abstract

Further delineation of the antigens characteristic of the Vi or gamma(2c) subgroup of gamma-globulin was carried out utilizing a number of rabbit and primate antisera. Two genetic antigens characteristic of this subgroup, Gm(b) and Gm(g), were also detected by precipitation techniques with certain of the antisera. These were clearly differentiated from antigens common to all proteins of this subgroup. The concentration, of Vi protein in normal and pathological sera from several population groups was measured quantitatively utilizing a variety of immunological procedures. All sera studied showed measurable levels. The mean value for Caucasian sera was 1.06 mg/ml, representing approximately 8% of gammaG-globulin. This agreed closely with a figure of 8.4% for the incidence of myeloma proteins of the Vi subgroup among all gammaG-myeloma proteins in Caucasians. A relationship was found between the Vi subgroup concentration and the specific genetic type of a given individual. Measurements of the Gm(b) genetic determinants, which are found solely in Vi-type proteins, brought forward this relationship. Gm(b+) individuals showed higher concentrations of Vi-type gamma-globulin than those who were Gm(b-), and this difference was statistically significant for both the homozygous and heterozygous states. It appeared that the structural genes for Gm(b+) polypeptide chains showed a greater synthetic capacity than those for Gm(b-) types. The possible significance of such effects in governing the relative composition of the antibody population in a given individual is discussed.

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 4163358      PMCID: PMC2138342          DOI: 10.1084/jem.125.1.177

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  21 in total

1.  A RELATIONSHIP BETWEEN THE H CHAIN GROUPS OF 7S GAMMA-GLOBULIN AND THE GM SYSTEM.

Authors:  H G KUNKEL; J C ALLEN; H M GREY; L MARTENSSON; R GRUBB
Journal:  Nature       Date:  1964-07-25       Impact factor: 49.962

2.  QUANTITATIVE DETERMINATION OF SERUM IMMUNOGLOBULINS IN ANTIBODY-AGAR PLATES.

Authors:  J L FAHEY; E M MCKELVEY
Journal:  J Immunol       Date:  1965-01       Impact factor: 5.422

3.  A GENETIC STUDY OF THE ANTIGENS ASSOCIATED WITH THE GM(B) FACTOR OF HUMAN GAMMA GLOBULIN.

Authors:  A G STEINBERG; R GOLDBLUM
Journal:  Am J Hum Genet       Date:  1965-03       Impact factor: 11.025

4.  The hydrolysis of rabbit y-globulin and antibodies with crystalline papain.

Authors:  R R PORTER
Journal:  Biochem J       Date:  1959-09       Impact factor: 3.857

5.  Zone electrophoresis.

Authors:  H G KUNKEL
Journal:  Methods Biochem Anal       Date:  1954

6.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

7.  Gm(s) and Gm(t): genetic determinants of human gamma-globulin.

Authors:  L Mårtensson; E van Loghem; H Matsumoto; J Nielsen
Journal:  Vox Sang       Date:  1966 Jul-Aug       Impact factor: 2.144

8.  Gm(g)--a "new" gamma-globulin factor.

Authors:  J B Natvig
Journal:  Nature       Date:  1966-07-16       Impact factor: 49.962

9.  ELECTROPHORETIC SEPARATION AND PROPERTIES OF MOUSE ANTIHAPTEN ANTIBODIES INVOLVED IN PASSIVE CUTANEOUS ANAPHYLAXIS AND PASSIVE HEMOLYSIS.

Authors:  R S NUSSENZWEIG; C MERRYMAN; B BENACERRAF
Journal:  J Exp Med       Date:  1964-08-01       Impact factor: 14.307

10.  H CHAIN SUBGROUPS OF MYELOMA PROTEINS AND NORMAL 7S GAMMA-GLOBULIN.

Authors:  H M GREY; H G KUNKEL
Journal:  J Exp Med       Date:  1964-08-01       Impact factor: 14.307

View more
  38 in total

1.  Herpesvirus serology, aberrant specific immunoglobulin G2 and G3 subclass patterns and Gm allotypes in individuals with low levels of IgG3.

Authors:  A Linde; R Söderström; C I Smith; M Sällberg; H Dahl; R Grubb; J Björkander; L Hammarström
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

2.  Involvement of both HLA and Ig heavy chain haplotypes in human IgA deficiency.

Authors:  P G Olsson; L Hammarström; D W Cox; C I Smith
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

3.  Allotype-associated differences in concentrations of human IgG subclasses.

Authors:  H Sarvas; N Rautonen; O Mäkelä
Journal:  J Clin Immunol       Date:  1991-01       Impact factor: 8.317

4.  Influence of Gm allotype on the IgG subclass response to streptococcal M protein and outer membrane proteins of Moraxella catarrhalis.

Authors:  R T Carson; D F McDonald; M A Kehoe; J E Calvert
Journal:  Immunology       Date:  1994-09       Impact factor: 7.397

5.  Factors influencing immunoglobulin levels.

Authors:  L S Salimonu
Journal:  Indian J Pediatr       Date:  1976-04       Impact factor: 1.967

6.  Recombination, mutation, or constitutive expression at a Gm locus and familial hypergammaglobulinemia.

Authors:  G Lefranc; L Rivat; J P Salier; E van Loghem; H Aydenian; P Zalzal; L Chakhachiro; J Loiselet; C Ropartz
Journal:  Am J Hum Genet       Date:  1977-09       Impact factor: 11.025

Review 7.  Neurogenic aspects of essential hypertension in man.

Authors:  G A FitzGerald
Journal:  Ir J Med Sci       Date:  1979-12       Impact factor: 1.568

8.  [IgG in chromosomal aberrations: quantitative expression of Gm allotypes and some IgG subclasses in family studies].

Authors:  L Rivat; M Daveau
Journal:  Humangenetik       Date:  1974

9.  Gammaglobulin allotypes in Finnish Lapps, Finns, Aland Islanders, Maris (Cheremis), and Greenland Eskimos.

Authors:  A G Steinberg; A Tiilikainen; M R Eskola; A W Eriksson
Journal:  Am J Hum Genet       Date:  1974-03       Impact factor: 11.025

10.  Metabolic properties of IgG subclasses in man.

Authors:  A Morell; W D Terry; T A Waldmann
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.